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Abstract
Background: The success of developing cardiovascular tissue engineering (CTE) grafts greatly needs a readily
available cell substitute for endothelial and interstitial cells. Perinatal annexes have been proposed as a valuable
source of mesenchymal stem cells (MSCs) for tissue engineering and regenerative medicine. The objective of the
present study is to evaluate the potential of human Wharton’s jelly MSCs (WJ-MSCs) and amniotic membrane MSCs
(AM-MSCs) as a seeding cell in CTE and cardiovascular regenerative medicine.
Methods: WJ-MSCs/AM-MSCs were isolated and characterized in vitro according to their morphology, proliferation,
self-renewal, phenotype, and multipotency. More importantly, the characteristics of hemocompatibility, extracellular
matrix deposition, and gene expression and viability of both MSCs were investigated.
Results: Fibroblast-like human WJ-MSCs and AM-MSCs were successfully isolated and positively expressed the
characteristic markers CD73, CD90, and CD105 but were negative for CD34, CD45, and HLA-DR. Both MSCs shared
trilineage differentiation toward the adipogenic, osteogenic, and chondrogenic lineages. The proliferative and
self-renewal capacity of WJ-MSCs was significantly higher than that of AM-MSCs (P < 0.001). WJ-MSCs provided
comparable properties of antiplatelet adhesion and did not activate the coagulation cascade to endothelial cells.
However, aggregated platelets were visualized on the surface of AM-MSCs-derived cell sheets and the intrinsic
pathway was activated. Furthermore, WJ-MSCs have superior properties of collagen deposition and higher viability
than AM-MSCs during cell sheet formation.
Conclusions: This study highlights that WJ-MSCs could act as a functional substitute of endothelial and interstitial
cells, which could serve as an appealing and practical single-cell source for CTE and regenerative therapy.
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Background
Although surgery and medication have achieved tremen-
dous progress, cardiovascular diseases still represent the
leading cause of morbidity and mortality in the developed
world [1, 2] and in China. [3] However, the shortage of
donor tissues and organs has limited the therapeutic op-
tion of end-stage cardiovascular diseases [4]. Therefore,
there is an urgent need to develop alternative therapy. In
the cardiovascular system, the tissue engineering approach
and mesenchymal stem cells (MSCs)-based regenerative
medicine are being pursued and increasingly regarded as
the promising solution for the development of viable sub-
stitutes of heart valves, blood vessels, myocardium, and
cardiac patch materials [4–6]. Cardiovascular tissue engin-
eering (CTE) focuses on the regeneration and replacement
of diseased cells, tissues, or organs to restore impaired
function using the knowledge and techniques of engineer-
ing, materials science, cell biology, and molecular biology.
For several years, CTE mainly relied on a “classical”
scaffold-cell-based paradigm, including the isolation and
expansion of seeding cells; subsequently, these cells are
seeded onto an appropriate scaffold after in vitro cultiva-
tion and finally implantated in vivo. Several challenges still
exist in the aim to generate functional cardiovascular grafts
and to explore effective cell therapies, searching for an ap-
propriate target cell is one of the primary challenges [7].
For decades, MSCs have been extensively explored as a
noncontroversial, multipotent, easily accessible, safely trans-
plantable, and new therapeutic cell source for tissue engin-
eering and regenerative medicine [8, 9]. Tissue engineering
and MSCs transplantation have been proposed as the most
promising strategies for the regeneration of impaired car-
diovascular tissues. As MSCs hold the advantages of hom-
ing, multi-differentiation, paracrine, immunomodulation,
and anti-inflammation capabilities; they have been widely
studied in the clinical arena (http://clinicaltrials.gov/) to al-
leviate a variety of debilitating disorders [10], such as acute
myocardial infarction [11], graft-versus-host disease [12],
autoimmune diseases, cystic fibrosis [13], and nerve regen-
eration, etc. [10, 14]. A number of donor tissue-derived
MSCs, including bone marrow, adipose tissue, skin, dental
pulp, hair follicle, perinatal tissue, and induced pluripotent
stem cells, have been evaluated and their phenotypes, pro-
liferative potential, multipotent differentiation potential,
and potent immunomodulatory properties identified [9, 10,
15, 16]. However, the therapeutic application of adult
tissue-derived MSCs, such as bone marrow and adipose,
may be limited by aging and diseases by decreasing their
quality and quantity [10, 17]. Furthermore, obtaining au-
tologous MSCs undergoes the disadvantages of invasive iso-
lation procedure, which would undermine the integrity of
local tissue and would be accompanied with significant
risks [17, 18]. Therefore, the clinical applications of an alter-
native MSCs source has to be further explored.
Perinatal annexes are seen as a biological waste post-
delivery and represent a reservoir of MSCs, as clinical-
scale cell numbers can be easily attained from several
perinatal annexes, such as umbilical cord blood,
Wharton’s jelly (the gelatinous matrix in the umbilical
cord), placental tissue, and amniotic membrane [18, 19].
MSCs isolated from perinatal annexes are ideal substi-
tutes, as they can overcome the limitations and disad-
vantages of adult MSCs as mentioned earlier. These
MSCs are maintained in the embryological phase and
represent a bridge between embryonic and adult stem
cells. As primitive MSCs, Wharton’s jelly MSCs (WJ-
MSCs) and amniotic membrane MSCs (AM-MSCs) have
been successfully isolated and identified as homogeneous
MSCs in Wharton’s jelly and amniotic membrane, and
they can be induced to differentiate into osteoblasts,
adipocytes, and chondrocytes. Moreover, WJ-MSCs have
been successfully induced to differentiate into cardio-
myocytes and endothelial-like cells at certain conditions
[20, 21]. WJ-MSCs are easily accessible and allow for cell
harvest from the donor without substantial risks and
sacrifice of intact donor tissues [22]. WJ-MSCs also can
be transplanted into the same donor and allow allogenic
transplantation without ethical and immunological
barriers; because it is an immunologically privileged sta-
tus, a single allogeneic WJ-MSCs donor may serve for
substantial patients. These advantages make WJ-MSCs
and AM-MSCs a fascinating source of stem cells for
CTE and could overcome the challenge of using mature
somatic cells from adult tissues. Thus, it is interesting to
compare the application potential of WJ-MSCs and AM-
MSCs for CTE and regenerative medicine.
To fulfill its roles in CTE, seeding cells must functionally
replace resident endothelial cells (EC) with antithrombo-
genic properties and terminally differentiated stromal cells
responsible for extracellular matrix (ECM) development
[23, 24]. Considering the observed efficiency of WJ-MSCs/
AM-MSCs and the previous studies of WJ-MSCs/AM-
MSCs-based cardiovascular regenerative medicine and
tissue engineering [25–28], it is surprising that so little
knowledge is known about the head-to-head comparison
of the properties of antiplatelet adhesion, hemocompatibil-
ity, and the profiles of ECM deposition and cell viability of
WJ-MSCs/AM-MSCs. Consequently, the motivation of the
present study is to compare the applications of WJ-MSCs/
AM-MSCs for CTE on hemocompatibility and ECM secre-
tion. Results demonstrated that WJ-MSCs are superior
seeding cells for developing tissue-engineered cardiovascu-
lar grafts.
Methods
Isolation and culture of MSCs
Primary human WJ-MSCs/AM-MSCs (n = 5, gestational
age 38–40 weeks) were isolated from human umbilical
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cord Wharton’s jelly and amniotic membrane as previ-
ously described [29]. Briefly, the umbilical cord and
amniotic membrane were obtained from a healthy baby
and rinsed thoroughly with phosphate-buffered saline
(PBS). The cord was maintained in PBS at 4 °C and
delivered to the laboratory and processed immediately.
After the umbilical cord arteries and vein were dissected,
the adventitia of umbilical cord was gently scraped using
a scalpel blade. The Wharton’s jelly and the amniotic
membrane were cut into small cubes and placed in
tissue culture dishes (Corning, Lowell, MA, USA) in a
sterile fashion. Explants were cultured in α-minimum
essential medium (α-MEM; Hyclone, Logan, UT, USA)
supplemented with 20% fetal bovine serum (FBS;
HyClone) and antibiotics (1% penicillin/streptomycin).
Subsequently, the culture dish was maintained at 37 °C
in a humidity incubator containing 5% CO2. The culture
medium was changed every third day until MSCs
migrated onto the culture dish. After 3 to 4 weeks, WJ-
MSCs/AM-MSCs were detached and passaged using
0.0625% trypsin while cells were propagated to reach 70
to 90% confluency. In these experiments, cells from the
third to fifth passages were used and maintained at 37 °C
in a humidified atmosphere containing 5% CO2.
Cell metabolism and proliferation
To investigate the cell metabolism and proliferation
potential, the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) colorimetric assay was used.
Briefly, WJ-MSCs and AM-MSCs suspensions were di-
luted to 2 × 103 cells ml-1 with α-MEM containing 10%
FBS. Then, 100 μL aliquots of WJ-MSCs and AM-MSCs
suspensions were seeded into 96-well plates (Corning)
and incubated at 37 °C in a humidified atmosphere with
5% CO2. After allowing 24 h for cell adherence and
proliferation, five wells of each group were used for the
MTT assay, which were carried out each day at the same
time of a 7-day culture period. A total volume of 20 μL
of 5 mg mL-1 MTT (Sigma-Aldrich, St. Louis, MO,
USA) solution was added to each well and incubated for
4 h, and then the medium was discarded. Subsequently,
150 μL dimethylsulfoxide (DMSO; MP Biomedicals,
Santa Ana, CA, USA) was added to dissolve formazan
salts, and the absorbance values for each well were mea-
sured using a spectrophotometer at 490 nm (Model 680;
Bio-Rad, Hercules, CA, USA).
Colony-forming unit fibroblast (CFU-F) assay
The self-renewal capacity of WJ-MSCs and AM-MSCs
was evaluated using the CFU-F assay. A total of 1 × 103
of WJ-MSCs or AM-MSCs (P4) were suspended in basal
cultivation medium and cultured in 100-mm-diameter
culture plates (Corning). These cells were washed on
day 14 with PBS and stained with 0.3% crystal violet
(Sigma-Aldrich) for 8 min at room temperature. Subse-
quently, the stained cultures were photographed and
analyzed by using inverted microscopy, and the colonies
with 50 or more cells were counted.
Immunophenotype analysis by flow cytometry
For the analysis of the immunophenotype and quantifi-
cation of antigen expression, flow cytometry was per-
formed by using antibodies against CD29, CD73, CD90,
CD105, CD146, α-smooth muscle actin (α-SMA), CD34,
CD45, and HLA-DR. Briefly, 6 × 105 WJ-MSCs/AM-
MSCs were washed with PBS three times and incubated
with fluorescein isothiocyanate (FITC)-CD90, CD105,
HLA-DR, α-SMA and phycoerythrin (PE)-CD73, CD34
and peridinin-chlorophyll protein (Percp)-CD29, and
CD45-conjugated mouse anti-human monoclonal anti-
bodies (BD Biosciences, San Jose, CA, USA) for 30 min
at room temperature in the dark. Isotype-matched IgGs
served as the control. Cells were subjected to flow
cytometric analysis using a Beckman Coulter Epics XL
instrument (Beckman Coulter, Fullerton, CA, USA).
Multi-lineage differentiation
The multi-lineage differentiation potential of WJ-MSCs
and AM-MSCs were determined by using the inducing
differentiation reagents, MSC go Adipogenic, MSC go
Osteogenic, and MSC go Chondrogenic (Biological
Industries, Kibbutz Beit-Haemek, Israel), according to
the manual’s instructions. Briefly, 1 × 105 WJ-MSCs or
AM-MSCs (P4) were cultured with a-MEM in six-well
plates without the addition of inducing regents until 80
to 90% confluence. Then, the culture medium was chan-
ged to adipogenic or osteogenic differentiation medium.
α-MEM supplied with 2% FBS served as the negative
control. The induction medium was refreshed at 3-day
intervals. For adipogenic identification, cells were fixed
with 10% formaldehyde after 4 weeks of culture and
stained with 0.3% Oil Red O (Sigma-Aldrich), and lipid
droplets were identified microscopically. For osteogenic
identification, cells were fixed with 4% paraformaldehyde
after 3 weeks of culture and stained with 2% Alizarin
Red S (pH 4.2; Kermel, Tianjin, China), and the depos-
ited calcification nodules were identified microscopically.
For chondrogenic differentiation, a total of 5.5 × 105
WJ-MSCs or AM-MSCs suspensions were centrifuged at
250 g for 5 min for obtaining cell pellets. After draining
the supernatant carefully, 1 ml of MSC go Chondrogenic
differentiation medium was added. The induction
medium was refreshed at 4-day intervals. α-MEM
supplied with 2% FBS served as the negative control.
After 3 weeks of cultivation, cells were fixed with 10%
formaldehyde for 24 h and embedded in paraffin. Sec-
tions (4 μm) were deparaffinized in xylene and stained
with Alcian Blue Staining Kit (ScienCell, Carlsbad, CA,
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USA) according to the user’s manual. Then, the morph-
ology of cartilage lacuna and sulfated proteoglycan were
identified.
Evaluation of platelet adhesion
Platelet adhesion was evaluated by incubating platelet-
rich plasma (PRP) with WJ-MSCs, AM-MSCs and
human umbilical vein endothelial cells (HUVECs) in 24-
well plates with one coverslip (tissue culture-treated;
8 mm) well-1. Non-cell-seeded wells were served as the
control. WJ-MSCs and AM-MSCs were grown in α-
MEM supplemented with 10% FBS and 1% penicillin/
streptomycin. HUVECs were provided by the Central
Laboratory of Yan’an Affiliated Hospital of Kunming
Medical University and cultured with EC growth
medium (Medium 200; Gibco, Grand Island, NY, USA)
supplemented with 2% FBS, epidermal growth factor
(EGF) 5 ng ml-1, basic fibroblast growth factor (bFGF)
3 ng ml-1, heparin 10 μg ml-1, bovine serum albumin
(BSA) 200 ng ml-1, hydrocortisone 1 ng ml-1, gentamicin
0.5 mg ml-1, and amphotericin B (25 μg ml-1). WJ-
MSCs, AM-MSCs, and HUVECs were passaged by tryp-
sinization (0.0625% trypsin/EDTA) until 90% confluence
and subcultured in 24-well plates at a density of 10,000
cells cm-2.
To obtain PRP, whole blood from a healthy adult
volunteer, free of medication, was drawn into a glass
syringe containing 3.8% sodium citrate (blood/sodium
citrate volume, 9:1), with informed consent. PRP was ac-
quired by centrifugation of the whole blood at 200 g for
10 min at 22 °C. After cell culture medium was drained
and rinsed two times with PBS, PRP was gently pipetted
onto cells in each well (200 μl well-1) and incubated for
30 min at 37 °C. Then, PRP was drained into the original
syringe and platelet counts were performed using an
automated routine blood analyzer (Sysmex XT-4000i;
Sysmex, Kobe, Japan). The plates were rinsed three times
with PBS (5 min each) with gentle agitation to eliminate
the weakly adhered platelets and then fixed in 4% glutar-
aldehyde for 24 h. Subsequently, the samples were
washed in PBS and dehydrated in a series of ethanol
solutions. Then subjected to critical-point drying and
sputter-coated with gold, the platelets that attached to
each surface were observed using a Hitachi S-3000 N
Scanning Electron Microscope (SEM; Hitachi, Tokyo,
Japan).
Hemocompatibility
More importantly, the hemocompatibility of WJ-MSCs
and AM-MSCs were investigated by the measurements
of prothrombin time (PT) and activated partial thrombo-
plastin time (APTT). Similar to platelet adhesion assess-
ment, whole blood was added to 24-well plates (1 ml
well-1) and incubated for 30 min at 37 °C. Then, the
blood was drained into a novel tube and centrifuged at
250 g for 10 min at 22 °C. PT and APTT were measured
using an automated blood coagulation analyzer (Sysmex
CS-5100). Control experiments were carried out using
HUVECs and normal blood sample. Each experiment
was repeated three times.
Preparation of cell sheet
The cryopreserved WJ-MSCs and AM-MSCs (P4) were
rapidly thawed and cultivated in α-MEM supplied with
10% FBS. At 90% confluence, cells were trypsinized and
seeded in a six-well plate (Corning) with a density of
1.0 × 105 cells cm-2 and cultured in α-MEM supplied
with 10% FBS, ascorbic acid (50 μg ml-1, Sigma-Aldrich),
and 1% penicillin/streptomycin. Cells were incubated in
a humidified atmosphere of 5% CO2, at 37 °C and
formed a cohesive living cell sheet. Normal mouse
thoracic aorta smooth muscle cell (SMC), A7r5 cell line
(mSMC-A7r5; Cell Bank of Kunming Institute of Zoology,
Chinese Academy of Sciences), served as the positive
control. mSMC-A7r5 was cultivated in high-glucose
Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) at
the same cell-seeding density and conditions. After 12 days
of preparation, inverted microscopic observations were
performed. The intact cell sheets of WJ-MSCs and AM-
MSCs were harvested from the plate by using a cell
scraper.
Histological assessment
Cell sheet samples were fixed for 24 h in 10% formalde-
hyde at room temperature followed by dehydration and
embedding in paraffin. Cross-sections (4 μm) were cut
on a microtome and mounted on glass slides. The
general morphology and structure were evaluated via
standard hematoxylin and eosin (H&E) staining. The
ECM of elastin laminae, collagen, and glycosaminogly-
can was investigated using Movat’s pentachrome staining
according to the manufacturer’s instructions (ScyTek
Laboratories, Logan, UT, USA). The H&E and Movat’s
pentachrome staining results were evaluated using a
Nikon DS-Ri1 compound microscope (Nikon, Tokyo,
Japan).
Electron microscope
Cell sheet samples were prepared for SEM and transmis-
sion electron microscopy (TEM) by fixation and dehydra-
tion. Briefly, cell sheets were washed with PBS and fixed
with 3.5% glutaraldehyde (Alfa Aesar, Ward Hill, MA,
USA) for 24 h at 4 °C. The samples were postfixed and
processed in 1% OsO4 and dehydrated in standard gradu-
ated ethanol series. After being critical-point dried and
sputter-coated with gold, the samples were imaged using a
Hitachi S-3000 N SEM.
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For TEM investigation, postfixation samples were
embedded in epoxy resin. Ultra-thin 60 nm sections
were cut and investigated using a JEOL 1011 TEM (Jeol,
Zaventem, Belgium) at 100 kV.
Quantification of ECM deposition
To evaluate the ECM secretion capacity of WJ-MSCs
and AM-MSCs during cell sheet preparation, Sircol™
soluble collagen assay and Fastin™ elastin assay (Biocolor,
Carrickfergus, UK) were performed.
To evaluate the collagen content of the acquired cell
sheet, the collagens were quantified using Sircol™ soluble
collagen assay according to the manufacturer’s instruc-
tions. Briefly, collagen was extracted by using acid-
pepsin solution (0.1 mg ml-1) with overnight incubation
at 4 °C. The supernatant was decanted off into a capped
conical microcentrifuge tube. Subsequently, the solution
was incubated at 0 °C overnight for isolation and
concentration. Then, collagen was dyed with Sirius Red.
After washing and draining, the absorbance of the dis-
solved collagen-bound dye was measured at 570 nm and
expressed as micrograms per well of six-well plate.
For investigation the elastin contents of the acquired
cell sheet, the Fastin™ elastin assay was used. Briefly,
elastin was isolated using 0.25 mol L-1 oxalic acid incu-
bated in a 100 °C water bath for 60 min of three cycles,
then, elastin was precipitated and dyed. After recovery
of elastin-bound dye, the absorbance was measured at
490 nm and expressed as micrograms per well of six-
well plate.
RNA isolation and real-time polymerase chain reaction
(real-time PCR)
Total RNA was extracted from WJ-MSCs- and AM-
MSCs-based cell sheets in each group and HUVECs
by using TRIzol reagent (Molecular Research Center,
Cincinnati, OH, USA). Approximately 2 to 5 μg total
RNA were converted to cDNA using the SuperScript
First-Strand Synthesis Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Real-time PCRs were performed
using the QuantiTect SYBR Green PCR Kit (Toyobo,
Osaka, Japan) and the Applied Biosystems 7500 Real-
time PCR Detection System (Applied Biosystems,
Foster City, CA, USA). Two independent experiments
were performed for each reaction, in triplicate. The
expression level of each gene was normalized to the
expression of β-actin. A portion of primer sets were
purchased from GeneCopoeia and the other primer
sets used in this experiment are listed in Table 1. Genes
and catalogue numbers of the purchased primer sets were
presented as follows: fibronectin, HQP006028; laminin,
HQP008000; nidogen, HQP011835; heparin sulfate pro-
teoglycan (HSPG), HQP009107; nitric oxide synthase
(NOS), HQP088415.
Live/dead assays for cell viability
After cell sheet preparation, the cell viability of each
sheets was characterized using fluorescence staining
with Live/Dead assay kit (Merck Millipore, Darmstadt,
German). Briefly, cell sheets were rinsed three times
with PBS and then incubated in a Live/Dead staining
solution according to the manufacturer’s instructions.
Then, the submerged cell sheets were incubated at 37 °C
for 60 min, washed with PBS, and examined with a
Nikon DS-Ri1 fluorescence microscope. The live cells
were visualized by green fluorescein and dead cells were
represented as red.
Statistical analysis
Unless otherwise noted, all experiments were performed
at least in triplicate (n = 5), and representative images
were reported. Quantitative experimental results were
expressed as the means ± SD. Statistical comparisons
were performed using unpaired sample t tests for two
Table 1 Primers sequences for gene expression analysis using real-time PCR
Genes Accession number Primer sequence (5′-3′) Product size (bp)
Collagen-I NM_000088.3 Forward: AAGGTGTTGTGCGATGACG
Reverse: TGGTCGGTGGGTGACTCTG
116
Collagen-IV NM_001303110.1 Forward: AGGAGACTTCGCCACCAA
Reverse: GGTCCTGTGCCTATAACAATT
264
Vimentin NM_003380.3 Forward: CTGAACCTGAGGGAAACTAA
Reverse: AGAAAGGCACTTGAAAGCT
231
Connexin-43 NM_000165.4 Forward: CAGTCTGCCTTTCGTTGT
Reverse: CTCTTCCTTTCGCATCAC
168
Vitronectin NM_000638.3 Forward: CAAAGGCTACCGTTCACAA
Reverse: AGACACTCTGGATGGGTTCA
182
Elastin NM_001278918.1 Forward: CGCTGGTGCTCTTATCTTC
Reverse: GCTTCAGGTGCTTGGGTA
176
β-Actin NM_005559.3 Forward: AGCGAGCATCCCCCAAAGTT
Reverse: GGGCACGAAGGCTCATCATT
285
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groups and one-way analysis of variance (ANOVA) and
Tukey’s post hoc test for more than two groups. Statis-
tical significance was accepted at P < 0.05.
Results
Culture and characterization of WJ-MSCs and AM-MSCs
Primary WJ-MSCs and AM-MSCs were successfully
isolated from human umbilical cord Wharton’s jelly and
amniotic membrane from all five donors and passaged
in vitro on a standard plastic surface. Both WJ-MSCs
and AM-MSC (Fig. 1a) exhibited long spindle-like struc-
tures and displayed a typical fibroblastic morphology.
An important issue of interest in seeding cells for tissue
engineering is the self-renewal and proliferative poten-
tial. The obtained MSCs were characterized in terms of
the CFU-F assay. Both types of cells displayed colony-
forming ability, and high colony-forming efficiencies
were observed in WJ-MSCs compared to AM-MSCs
(Fig. 1b). The number of CFU-F per 100 WJ-MSCs
(23.7% ± 4.5%) was significantly higher than that of AM-
MSCs (11.1% ± 3.0%; P < 0.001; Fig. 1c). The proliferation
and metabolic activity of WJ-MSCs were significantly
higher than that of AM-MSCs after 2 days of incubation
(P < 0.001), although they exhibited a similar metabolic
activity on the seventh day (Fig. 1d).
Flow cytometric assay was performed with MSCs
derived from Wharton’s jelly and amniotic membrane
tissues. Results revealed a typical pattern for MSCs
[positive expression of CD29, CD73, CD90, CD105;
partial expression of CD146, α-SMA (a typical SMC
marker); and negative expression of CD34, CD45, and
HLA-DR], indicating that WJ-MSCs and AM-MSCs
were representative of a MSCs-like population
(Fig. 2).
When WJ-MSCs and AM-MSCs were cultured in
conditional induction medium, cells were subjected to
adipogenic, osteogenic and chondrogenic differentiation
(Fig. 3). Adipogenic differentiation was verified by the
accumulation of cytoplasmic lipid vacuoles and Oil Red
O staining. Osteogenic differentiation was revealed by
Alizarin Red S-positive mineral deposits, which indi-
cated the WJ-MSCs’ and AM-MSCs’ osteogenic po-
tential. Moreover, chondrogenic differentiation was
evaluated by Alcian Blue staining with ECM, such as
collagen and glycosaminoglycans. These results sug-
gested that WJ-MSCs and AM-MSCs were successfully
isolated from the human umbilical cord Wharton’s jelly
and amniotic membrane tissues. Furthermore, WJ-MSCs
are a primitive stem cell population with higher applica-
tion potential.
Fig. 1 Isolation and characterization of clonogenic and proliferative potential of WJ-MSCs and AM-MSCs. a Morphologies of WJ-MSCs and AM-MSCs
observed under inverted microscopy. b Representative images showing the colony number and a single clone of CFU-Fs observed from WJ-MSCs and
AM-MSCs. c Cumulative CFU-F numbers of WJ-MSCs and AM-MSCs. d Proliferation and metabolism of WJ-MSCs and AM-MSCs as investigated by the
MTT assay. (c and d) Mean ± SD of five independent donors. *P< 0.001, significant difference between the two cell sources (CFU-F and MTT assays at the
same time point). AM-MSCs amniotic membrane mesenchymal stem cells, CFU-F colony-forming unit fibroblast, WJ-MSCs Wharton’s jelly mesenchymal
stem cells
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Platelet adhesion and hemocompatibility of WJ-MSCs and
AM-MSCs
A dogma in the construction of CTE substitutes is to
seed EC as a confluent surface to prevent thrombosis.
To investigate the antithrombogenic properties of WJ-
MSCs and AM-MSCs, HUVECs-seeded (negative) and
non-cell-seeded (positive) cultivation plate surfaces
served as the controls and healthy donor blood was
used. As expected, adhered and aggregated platelets
were obviously observed on the non-cell-seeded plate
surface (Fig. 4h), which represented coral-like structures.
WJ-MSCs (Fig. 4d) and HUVECs (Fig. 4b) represented
similar antiplatelet adhesion properties; however, platelet
adhesion and aggregation was observed on the AM-
MSCs-seeded surface (Fig. 4f ). Quantitative analysis of
platelets in the plasma also demonstrated significantly
higher platelet number of HUVECs and WJ-MSCs than
that of AM-MSCs and non-cell-seeded surface (P < 0.05;
Fig. 4g). There was no significant difference between
blood sample, HUVECs, and WJ-MSCs (P > 0.05). More-
over, there was no significant difference between AM-
MSCs and non-cell-seeded surface (P > 0.05). These re-
sults revealed that WJ-MSCs had antiplatelet adhesion
properties similar to HUVECs.
Results of the hemocompatibility assessment of WJ-
MSCs, AM-MSCs, and HUVECs are presented in Fig. 5.
As expected, the extrinsic (PT) and intrinsic (APTT)
pathways of the coagulation cascade were not activated
with WJ-MSCs; however, the intrinsic pathway was acti-
vated with AM-MSCs. There was no significant
difference of PT in groups (Fig. 5a) and the APTT of the
WJ-MSCs was approximated to blood sample (P > 0.05).
However, the APTT of the HUVECs was prolonged and
the AM-MSCs was shortened (P < 0.05). These data
strongly suggest that WJ-MSCs can be used as an alter-
native seeding cell to EC in CTE.
Histology of cell sheet
To be effective in practical applications of seeding cells
for CTE, ECM must be produced and organized by
seeding cells. To evaluate cell sheet assembly and ECM
deposition, WJ-MSCs, AM-MSCs, and mSMA-A7r5
were cultured in basic medium supplied with 10% FBS
and ascorbic acid (50 μg/ml). Results showed that both
types of MSCs deposit a certain amount of ECM and
formation of cell sheet; however, the cell sheet was not
successfully generated of mSMA-A7r5. MSCs-derived
sheets were observed with inverted microscope and
demonstrated confluent cell connection (Fig. 6a).
H&E staining of cross-sectional samples revealed that
both WJ-MSCs and AM-MSCs sheets were four to five
layers, and ECM spread uniformly as a three-dimensional
structure. However, more stained nuclei were visualized in
the WJ-MSCs sheets (Fig. 6b). Next, fibrous ECM
structure and deposition of the cell sheet samples were
analyzed by Movat’s pentachrome staining. As expected,
Fig. 2 Identification of the immunophenotype of WJ-MSCs and AM-MSCs at P3 by flow cytometric analysis. a Representative result from five
independent experiments. b Percentage of surface marker expression of WJ-MSCs and AM-MSCs. Mean ± SD of five independent experiments.
AM-MSCs amniotic membrane mesenchymal stem cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells
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the presence of a dense extracellular matrix rich in pro-
teoglygcans (blue) in which cells were embedded; never-
theless, there was no obviously stained collagen
(yellow) and elastin (brown; Fig. 6c). The ECM was
homogeneous and did not present any significant dis-
crepancy between them.
Electron microscope
As expected, SEM showed the surface morphology of
both WJ-MSCs and AM-MSCs sheets were spread and
elongated, and a dense film-like confluent cell network
was formed and retained tight cell junctions (Fig. 7a). Sub-
sequently, the intracellular ultrastructures of both cell
sheets were examined by TEM (Fig. 7b and c). The data
indicated that the acquired cell sheets preserved the inter-
cellular junctions and endogenous ECM. Collagen fibrils
were present at a high density in the cell sheets. The colla-
gen fibers concentrated into clusters and were distributed
in random directions throughout the cell sheets.
ECM quantification and real-time PCR
Histological and electron microscope results showed
that ECM was deposited by WJ-MSCs and AM-MSCs
during the process of cell sheet formation. However, the
ECM secretion ability of both MSCs was still unknown.
The secretion of the major ECM proteins, such as colla-
gen and elastin were determined by using Sircol™ soluble
collagen assay and Fastin™ elastin assay (Fig. 8). Results
suggested that WJ-MSCs had a more preferable nature
of collagen secretion than AM-MSCs (P < 0.001). On the
contrary, AM-MSCs had a significant property of elastin
deposition than WJ-MSCs (P < 0.001).
To further evaluate the transcript expression levels of
selected ECM genes (including collagen I, collagen IV,
connexin-43, vimentin, vitronectin, fibronectin and elas-
tin) and defined basement membrane genes (laminin
and nidogen) of both WJ-MSCs- and AM-MSCs-derived
cell sheets, real-time PCR was performed. Results are
presented in Fig. 9. Data revealed that the expression of
collagen I, collagen IV, connexin-43, and laminin of WJ-
MSCs sheets was significantly higher than that of AM-
MSCs sheets (P < 0.001). However, the expression of
vitronectin, fibronectin, and elastin of the WJ-MSCs
sheets were significantly lower than that of the AM-
MSCs sheets (P < 0.001). There was no significant statis-
tical difference of vimentin and nidogen between the
WJ-MSCs and AM-MSCs sheets (P > 0.05).
To elucidate the underlying mechanism of the anti-
platelet adhesion properties and the nonactivation of the
intrinsic coagulation pathway of WJ-MSCs, the expres-
sion of antithrombogenic gene HSPG and endothelial
NOS was determined using real-time PCR. Results are
presented in Fig. 10. Results demonstrated significantly
higher expression of HSPG of HUVECs than that of WJ-
MSCs and AM-MSCs (P < 0.001). Interestingly, the ex-
pression of HSPG of WJ-MSCs was significantly higher
than that of AM-MSCs (P < 0.001). There was no signifi-
cant statistical difference of NOS expression between
HUVECs, WJ-MSCs, and AM-MSCs (P > 0.05).
Effects of cell sheet formation on cell viability
To obtain functional substitutes and provide more insights
into the viability differences of WJ-MSCs, AM-MSCs, and
mSMA-A7r5, the Live/Dead assessment was performed.
The live cells stained green and the dead cells stained red
(Fig. 11). WJ-MSCs sheets exhibited the more superior
activities than the AM-MSCs sheets and mSMA-A7r5
demonstrated the worst activities. This data indicated that
WJ-MSCs were a suitable cell source for cardiovascular re-
generation and the construction of CTE grafts.
Discussion
This work highlights the potential of the WJ-MSCs to
produce CTE constructs as a suitable cell source. The
Fig. 3 Representative images of multi-lineage differentiation potential
of isolated WJ-MSCs and AM-MSCs. WJ-MSCs and AM-MSCs were
induced to differentiate toward adipogenic lineage and verified by
Alizarin Red S staining (magnification, ×100), osteogenic lineage and
verified by Oil Red O staining (magnification, ×200), and chondrogenic
lineage and verified by Alcian Blue staining (magnification, ×200). Scale
bar, 100 μm. AM-MSCs amniotic membrane mesenchymal stem cells,
WJ-MSCs Wharton’s jelly mesenchymal stem cells
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Fig. 4 Antiplatelet adhesion properties of WJ-MSCs and AM-MSCs. Morphologies of HUVECs (a), WJ-MSCs (c), and AM-MSCs (e). Representative
SEM images of platelets adhered, HUVECs (b), WJ-MSCs (d), AM-MSCs (f), and non-cell-seeded control group (h). White arrow indicates the
aggregated platelets. (g) Quantitative evaluation of nonadherent platelets in plasma. Mean ± SD. *P > 0.05, no statistical significance between
groups; **P < 0.05, significant difference between groups. AM-MSCs amniotic membrane mesenchymal stem cells, HUVECs human umbilical vein
endothelial cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells
Fig. 5 PT and APTT of different cells and normal blood samples. Mean ± SD of five independent experiments performed in triplicate. *P > 0.05;
**P < 0.05; ***P < 0.001. APTT activated partial thromboplastin time, AM-MSCs amniotic membrane mesenchymal stem cells, HUVECs human
umbilical vein endothelial cells, PT prothrombin time, WJ-MSCs Wharton’s jelly mesenchymal stem cells
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cardiovascular system has a low regenerative capability,
which makes the development of tissue engineering the
practicable alternative in cardiovascular tissue regener-
ation. To construct a functional CTE substitute, a suit-
able seeding cell is needed, which acts as the functional
substitute for autologous cells. It must be rapidly
expanded in vitro to obtain sufficient numbers for basic
research as well as clinical applications. Moreover, ideal
seeding cell should be accessible, isolated, be capable of
rapid expansion in in vitro culture, have immunology
and hematology compatibility, and be capable of long-
term survival and integration. In the field of cell-based
CTE and regenerative medicine, there are two seeding-
cell models typically pursued. Initially, CTE involved the
isolation and expansion of autologous cells from vascular
donor tissues [30]. Recently, a variety of tissue-derived
MSCs have provided a viable cell source for future regen-
eration of cardiovascular tissues, resulting from their
inherent ability of self-renewal and rapid proliferation
[31]. Perinatal annexes can be collected without invasive
procedures and ethical constraints. They provide an inex-
haustible source of MSCs. In particular, perinatal annex-
Fig. 6 Representative microscopic images and histology evaluation of WJ-MSC- and AM-MSC-derived cell sheets. a Acquired cell sheet imaged
by an inverted microscope on day 12 (magnification, ×100). b H&E staining of WJ-MSC- and AM-MSC-derived cell sheets. Scale bar, 100 μm.
c Movat’s pentachrome staining of WJ-MSC- and AM-MSC-derived cell sheets. Scale bar, 100 μm. AM-MSCs amniotic membrane mesenchymal
stem cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells
Fig. 7 Representative images of electron microscopic analysis of WJ-MSC- and AM-MSC-derived cell sheets. (a) SEM images of the surface of both
cell sheets. Scale bar, 50 μm. (b and c) TEM images of the ultrastructure of the ECM and collagen fibers (white arrow) within both cell sheets. Scale
bar, 5 μm (b) and 1 μm (c). AM-MSCs amniotic membrane mesenchymal stem cells, ECM extracellular matrix, SEM scanning electron microscope,
TEM transmission electron microscopy, WJ-MSCs Wharton’s jelly mesenchymal stem cells
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derived MSCs are a predominantly suitable source of
MSCs, which are maintained in the embryological phase
and retain some of the primitive stemness properties, and
possess superior naivety and plasticity than adult
tissue-derived MSCs and could be better suited for
cardiovascular regeneration [7, 32, 33]. Furthermore,
umbilical cord Wharton’s jelly and amniotic mem-
brane provide a preferable tissue source of MSCs
resulting from their easier accessibility and availability
for homotransplantation. These inherent advantages
make WJ-MSCs and AM-MSCs suitable sources for
CTE and further studies should be performed. Thus,
the data of the present study revealed that WJ-MSCs
were a desirable seeding cell for CTE, which yielded
superior advantages of cell proliferation, antiplatelet
adhesion, hemocompatibility and viability than AM-
MSCs. Moreover, WJ-MSCs demonstrated similar
ECM deposition capacity to AM-MSCs during cell
sheet preparation.
In the design of our experiments, WJ-MSCs and
AM-MSCs isolation and characterization from perinatal
annexes were achieved first. To compare MSCs derived
from umbilical cord Wharton’s jelly and amniotic mem-
brane, the proliferation and self-renewal capacity, the ex-
pression of specific surface antigens, and the multipotent
differentiation potential were characterized according to
the minimal criteria for MSCs recommended by the
International Society of Cell Therapy (ISCT) [34]. Results
demonstrated that both WJ-MSCs and AM-MSCs exhib-
ited a similar morphology (Fig. 1a), immunophenotype
(Fig. 2), and trilineage differentiation capacities (Fig. 3),
and both met the definition established for MSCs by the
ISCT. Furthermore, flow cytometry analysis showed that
both WJ-MSCs and AM-MSCs partially expressed CD146
and α-SMA (Fig. 2). CD146 is one of the markers of peri-
cytes [35, 36] and α-SMA is one of the differentiation
markers expressed by vascular SMC [37]. Pericyte and
SMC are the two major cell types of blood vessels. The
Fig. 8 Quantitative analysis of collagen and elastin of WJ-MSC- and AM-MSC-derived cell sheets. Mean ± SD of five independent experiments
performed in triplicate. ***P < 0.001. AM-MSCs amniotic membrane mesenchymal stem cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells
Fig. 9 Expression of ECM-related genes, including collagen I, collagen IV, connexin-43, vimentin, vitronectin, and elastin of both WJ-MSC- and
AM-MSC derived cell sheets as determined by real-time PCR. The expression levels were normalized to that of β-actin. Mean ± SD of five
independent experiments performed in triplicate. *P > 0.05; ***P < 0.001. AM-MSCs amniotic membrane mesenchymal stem cells, WJ-MSCs
Wharton’s jelly mesenchymal stem cells
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presence of CD146 and α-SMA indicated that both
WJ-MSCs and AM-MSCs populations are suitable for
the development of tunica media and adventitia for
tissue engineering vascular grafts.
Interestingly, this study demonstrated that the prolifer-
ation and self-renewal capacity of WJ-MSCs was signifi-
cantly higher than AM-MSCs (P < 0.001). As shown in
Fig. 1, WJ-MSCs consistently grow faster and have a
higher frequency of CFU-F than AM-MSCs. WJ-MSCs
have a rapid population doubling time and superior self-
renewal capability, and this property could overcome the
limitations of the slow growth rate with mature somatic
cells, such as SMC and EC, the most popular seeding
cells for CTE. These results suggest that WJ-MSCs can
easily fulfill the need of clinical scale with a higher
expansion capacity than AM-MSCs. The superior prolif-
erative and self-renewal potential of WJ-MSCs may be
associated with the higher expression of telomerase and
stemness gene [38–40]. Hsieh et al. demonstrated that
the gene expression involved in the phosphoinositide
3-kinase (PI3K)-AKT survival/proliferation pathway of
WJ-MSCs was higher than that of bone marrow MSCs
(BM-MSCs) [32]. Besides, several studies have demon-
strated that WJ-MSCs with a low immunogenicity did not
express the costimulatory complex (e.g., CD40, CD80, and
CD86) and HLA-DR on their surface and characterized by
broad immunomodulation properties [41–43]. These
studies revealed that WJ-MSCs would be tolerated in
allogenic transplantation.
The healthy EC is inherently nonthrombogenic and
plays the essential role in regulating thrombosis and
vascular tone. When CTE grafts are implantated and
come into contact with blood, a number of thrombotic
events occur, which correlate to CTE prostheses exposed
to blood. To prevent thrombosis and activation of the
coagulation cascade, EC had been seeded on biomate-
rials before implantation in a number of applications
[24, 44, 45]. Therefore, HUVECs were used as a positive
control in this study for investigation of the antiplatelet
adhesion and hemocompatibility properties of WJ-MSCs
and AM-MSCs.
In the construction of CTE grafts for clinical application,
the achievement and maintenance of a confluent antiplate-
let surface in the lumen is being pursued to improve blood
compatibility and host integration and EC is widely ac-
cepted as an exclusively seeding cell. However, autologous
EC has a limited proliferative capacity due to the age and
disease status of the patient and the long time course of
EC isolation and cultivation [46, 47]. Regarded as a
Fig. 10 Expression of HSPG and NOS of both WJ-MSC- and AM-MSC-derived cell sheets as well as HUVECs. Mean ± SD of five independent
experiments performed in triplicate. *P > 0.05; ***P < 0.001. AM-MSCs amniotic membrane mesenchymal stem cells, eNOS endothelial nitric oxide
synthase, HSPG heparin sulfate proteoglycan, HUVECs human umbilical vein endothelial cells, WJ-MSCs Wharton’s jelly mesenchymal stem cells
Fig. 11 Representative fluorescence microscopic images of Live/
Dead analysis of WJ-MSC- and AM-MSC-derived cell sheets and
mSMC-A7r5. Live cells were stained green and dead cells were
stained red. WJ-MSCs and AM-MSCs were primarily alive and dead
cells were relatively few. Scale bar, 100 μm. AM-MSCs amniotic
membrane mesenchymal stem cells, WJ-MSCs Wharton’s jelly
mesenchymal stem cells
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functional substitute for EC, a number of seeding cells have
been investigated for the construction of CTE grafts, such
as endothelial progenitor cells (EPCs) [48, 49], BM-MSCs
[50, 51], induced pluripotent stem cells (iPS) [52],
and WJ-MSCs-transdifferentiated EC [53].
The results of this study are the first confirming the
particular properties of WJ-MSCs of antiplatelet adhe-
sion and nonactivation of the intrinsic pathway in vitro.
SEM evaluation demonstrated that no aggregated plate-
lets were found on the surface of WJ-MSCs-based cell
sheets, and it was similar to HUVECs. However, aggre-
gated platelets were visualized on the surface of AM-
MSCs-based cell sheets (Fig. 4f ). In addition, the quanti-
fication analysis of platelets demonstrated significant
reduction (P < 0.001) in AM-MSCs- and non-cell-seeded
groups compared to HUVECs- and WJ-MSCs-seeded
groups as well as normal blood sample (Fig. 4g). Similar
to this study, Zhao et al. showed that BM-MSCs had
similar antiplatelet adhesion properties to EC [54].
Furthermore, Hashi et al. also revealed the unique
antithrombogenic property of BM-MSCs due to the
expression of HSPG on the BM-MSC surface [50].
Generally, blood coagulation is described in two
phases, wherein primary platelets aggregate formation
followed by the activation of the coagulation cascade to
form the fibrin clot. In the blood coagulation cascade,
thrombogenesis is initiated by the activation of the ex-
trinsic or intrinsic pathway [44]. The PT and APTT tests
are widely used in clinical diagnostic detection of abnor-
mality in the extrinsic and intrinsic pathways, respect-
ively [55, 56]. The shortening of either time indicates the
activation and the prolongation of either time indicates a
deficiency or inhibition of the respective cascade. In this
work, the APTT of AM-MSCs was significantly short-
ened and HUVECs was significantly prolonged com-
pared to that of normal blood sample and WJ-MSCs
(Fig. 5b). In this study, real-time PCR analysis showed
that WJ-MSCs had higher expression of HSPG than
AM-MSCs (Fig. 10), which may be the important
mechanism contributing to the WJ-MSCs’ resistance to
platelet adhesion, and had superior hemocompatibility.
These data demonstrated that WJ-MSCs had superior
hemocompatiblity than AM-MSCs, including antiplatelet
adhesion and avoidance of the activation of intrinsic
coagulation pathway. These traits make WJ-MSCs an
ideal cell source to construct CTE grafts.
Besides hemocompatibility requirements, the deposition
of new ECM by the seeding cell is another critical
challenge for CTE graft remodeling and regeneration as
well as assembling into a functional substitute. Moreover,
secretion of ECM by seeding cell is crucial to prevent the
degeneration of the graft structure [7, 57]. Three-
dimensional tissues reconstructed using the self-assembly
approach of cell sheets represent excellent tools to explore
the properties of ECM deposition and remodeling in vitro
and the ECM is deposited and organized endogenously by
the cells. Consequently, this study investigated the ECM
secretion properties of WJ-MSCs and AM-MSCs based
on scaffoldless cell sheet engineering. The cell sheet is an
effective approach to explore ECM deposition. In a sem-
inal article by L’Heureux et al., tissue engineering blood
vessels were successfully produced by combining the
ECM production nature of vascular SMC and fibroblasts
and the hemocompatibility of EC [58]. However, this
source of SMC, fibroblast, and EC are not compatible with
a fully homologous approach. SMC from elderly persons
have limited proliferative capability and a reduction in
collagen production, which impair the application of CTE,
especially in engineered vascular grafts [59]. To fulfill the
expectancy of ECM deposition, it would be preferable to
seek another potential source of SMC and fibroblasts. The
results of this study revealed that both WJ-MSCs and
AM-MSCs possess the property of ECM deposition. To
the best of the authors’ knowledge, these results initially
revealed that WJ-MSCs hold superior properties of colla-
gen deposition and high expression of connexin-43,
vimentin, laminin, as well as HSPG; however, AM-MSCs
have preferable capability of elastin secretion and high
expression of vitronectin and fibronectin. In a previous
study, Huang et al. demonstrated that BM-MSCs sheets
retained endogenous extracellular matrices and improved
post-infarcted cardiac function after transplanted in a
porcine model [60]. Furthermore, data from Au et al.
suggested that BM-MSCs are perivascular cell precursors
and functioned as perivascular cells for ECM deposition
and BM-MSCs may serve as seeding cells for construction
of tissue engineering vascular graft [61]. In consider-
ation of the ECM assembly capacity of adipose stem
cell, adipose stem cell-derived cell sheets have been
successfully used in the treatment of myocardial in-
farction [62] and production of tissue-engineered vas-
cular grafts [63]. These studies demonstrated that
adult MSCs have the properties of ECM deposition
and hold extensive application prospects and feasibil-
ity in CTE. In view of their properties of ECM
secretion and cell sheet formation, we think that both
WJ-MSCs and AM-MSCs are suitable for myocardial
regeneration.
Another important parameter in MSCs-based clinical
application is the cell survival and retention posttrans-
plantation at the injury sites. In clinical settings, the
resulting living MSCs reflect the biological properties of
the terminal CTE grafts and cell sheet-based regenera-
tive medicine. In this report, the cell viability profiles of
WJ-MSCs, AM-MSCs, and mSMA-A7r5 were investi-
gated by using Live/Dead cell viability assessment
(Fig. 11). The results revealed that WJ-MSCs hold the
highest viability after cultivation 14 day in vitro.
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This study has some potential limitations. Importantly,
this is an in vitro study to describe the potential of
WJ-MSCs and AM-MSCs in CTE and cardiovascular
regeneration. Although there are promising results
with WJ-MSCs, in vivo studies are required to evaluate
the regenerative and clinical translational properties of
WJ-MSCs, such as construction-engineered blood vessels
and myocardial infarction therapy. Moreover, further ex-
periments will be needed to ascertain the exact molecular
mechanism of WJ-MSCs antiplatelet adhesion and the
other biological properties of WJ-MSCs as a substitute of
EC, such as regulation of systemic blood flow, vascular
tone, vascular inflammation and others. These further
evaluations may accelerate the use of WJ-MSCs in clinical
practice from bench to bedside.
Conclusions
In summary, data from this study demonstrated that a
positive role of WJ-MSCs to behave as endothelial and
interstitial cells, which could act as a functional cell
source for CTE and clinical cardiovascular regeneration.
WJ-MSCs possess preferable proliferation capability and
comparable properties of antiplatelet adhesion and did
not activate the coagulation cascade to EC. However,
platelet aggregation was visualized on the surface of
AM-MSCs-derived cell sheets and the intrinsic pathway
was activated. Furthermore, WJ-MSCs have superior
properties of collagen deposition and higher viability than
AM-MSCs during cell sheet formation. Taken together,
WJ-MCSs could serve as an appealing and practical
single-cell source for cardiovascular tissue engineering
and regenerative therapy.
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